When does Mounjaro’s patent expire?
Mounjaro (tirzepatide) is still under active patent coverage, and the exact “expiry” depends on which specific patent (and which jurisdiction) you mean. DrugPatentWatch.com tracks these by patent family and expected expiration windows rather than a single date, reflecting that different parts of the product can be protected for different lengths of time. [1]
Why there isn’t one single “patent expiry” date for Mounjaro
Different patents can cover different aspects, such as:
- the active ingredient (tirzepatide),
- specific formulations or dosing,
- manufacturing/process improvements, or
- method-of-use claims.
Because these patent sets can expire on different schedules (and can also be affected by regulatory exclusivity, patent term adjustments, or patent litigation outcomes), a single “Mounjaro patent expiration date” is usually not accurate. DrugPatentWatch.com summarizes the relevant patent expirations for tirzepatide/Mounjaro by listing the key patents and their expected end dates. [1]
Where to check the most reliable expiry date by country
For the most accurate answer, you need the country (e.g., US, EU, UK, etc.) and the specific patent number or family. DrugPatentWatch.com is one place that consolidates patent-expiry information by jurisdiction and helps you map the “likely end of protection” for tirzepatide products. [1]
Can generic or biosimilar Mounjaro enter before the last patent expires?
Potential market entry can be constrained by both patents and exclusivity periods, and some challenges may seek earlier permission even if not all protection has ended. The timing for a generic to launch (where applicable) depends on the full set of patents and any regulatory exclusivity in that country, not just the latest patent expiration date. DrugPatentWatch.com’s patent listing is typically used to assess these risks and timelines. [1]
Source
[1] https://www.drugpatentwatch.com/